The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

A test commonly used to confirm a condition linked to high blood pressure is often inaccurate, causing doctors to skip ...

Semaglutide, the blockbuster drug better known by brand names like Ozempic and Wegovy, has now shown significant promise in ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor ...

I t’s hard to overstate just how revolutionary the development of medications like Ozempic and Wegovy has been for managing ...

recently started a phase 2 study of CagriSema – its combination of semaglutide with dual amylin and calcitonin receptor agonist cagrilintide – that will investigate its effects on liver damage ...

Rybelsus (semaglutide) is the first GLP-1 agonist ... "providing patients with another option to treat the disease without injections," according to the panel. The new oral drug is viewed as ...

The reserarchers found that a weekly dose of semaglutide was effective at treating Metabolic Dysfunction-Associated ...